Cerebrum

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Retrieved on: 
Tuesday, November 28, 2023

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.

Key Points: 
  • Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
  • ET [Platform D | Epilepsy Therapies]
    Summary: Combined preclinical and clinical data demonstrate PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy.
  • Summary: This study provides novel insights into the clinical validity of commonly used preclinical seizure models across the clinical epilepsy spectrum.
  • Oral presentation highlighting clinical updates from our PRAX-562 small molecule platform at the annual clinician, researcher, and family gathering for SCN8A

Cerebrum Announces Bi-directional Digital Pathology Integration

Retrieved on: 
Wednesday, September 13, 2023

BALTIMORE, Sept. 13, 2023 /PRNewswire-PRWeb/ -- Cerebrum™, a provider of Laboratory Information Systems (LIS) software, announced a new capability and partnership with Gestalt Diagnostics from the 2023 NSH Convention to help pathologists increase their productivity and accuracy. Cerebrum's LABdivus® now supports a bi-directional digital pathology integration with Gestalt's award winning digital platform, PathFlow®. This advanced digital image management system and viewer seamlessly integrates with LABdivus, enabling pathologists to automatically showcase slides in PathFlow for interpretation and diagnosis*. Utilizing PathFlow built-in viewing and AI algorithm capabilities, the pathologist can easily integrate the image snapshots and AI findings directly back into the LABdivus case for complete diagnosis and sign-out capabilities. Using PathFlow and LABdivus together provides a complete digital cockpit experience, improving the workflow and increasing the capabilities and diagnosis efficiency for the pathologist.

Key Points: 
  • Cerebrum™, a provider of Laboratory Information Management Systems (LIMS) software, announced a bi-directional digital pathology integration with Gestalt's award winning digital platform, PathFlow®, from the 2023 NSH Convention, to help pathologists increase their productivity and accuracy.
  • Cerebrum's LABdivus® now supports a bi-directional digital pathology integration with Gestalt's award winning digital platform, PathFlow®.
  • Cerebrum™ is a leader in providing high performance workflow systems for the anatomic pathology, genomics, and oncology laboratories.
  • Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently.

WELL Health Launches WELL AI Voice: The Ultimate Ambient AI Scribe to Give Physicians Their Time Back

Retrieved on: 
Wednesday, May 10, 2023

WELL AI Voice is the first of many future products/services launched under the new WELLHealth.ai program.

Key Points: 
  • WELL AI Voice is the first of many future products/services launched under the new WELLHealth.ai program.
  • Test results have demonstrated that physicians are experiencing a timesaving of up to 30% when using WELL AI Voice.
  • "Today marks a major milestone for WELL as we launch WELL AI Voice," said Amir Javidan, COO of WELL Health Technologies.
  • WELL AI Voice is the first of many AI capabilities we plan to introduce as part of our WELLHealth.ai program."

Cerebrum's IoT Tire Sensor Technology Gains Market Traction

Retrieved on: 
Tuesday, April 11, 2023

 LOS ANGELES, April 11, 2023 /PRNewswire/ -- Cerebrum Sensor Technologies announced that it has commercially launched its Intelligent Tire Solutions with leading vehicle and tire OEMs. Cerebrum's full suite of solutions utilize tire sensors and proprietary algorithms to monitor advanced tire conditions including pressure, temperature, tread health, load, alignment and more,  enabling users to enhance tire life while improving vehicle safety, performance, and sustainability.

Key Points: 
  • LOS ANGELES, April 11, 2023 /PRNewswire/ -- Cerebrum Sensor Technologies announced that it has commercially launched its Intelligent Tire Solutions with leading vehicle and tire OEMs.
  • Cerebrum's full suite of solutions utilize tire sensors and proprietary algorithms to monitor advanced tire conditions including pressure, temperature, tread health, load, alignment and more,  enabling users to enhance tire life while improving vehicle safety, performance, and sustainability.
  • Cerebrum offers the world's first and only real-time, direct tread depth monitoring solution, which is scalable to nearly any vehicle tire.
  • Cerebrum's Intelligent Tire Solutions have been tested and proven through large scale trials with dozens of OEMs, fleets and TPMS companies.

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Retrieved on: 
Monday, March 13, 2023

The initial placebo-controlled double-blinded Phase 2 RESCUE-ALS results were strengthened further with evidence of a survival benefit and preserved function at one year and beyond.

Key Points: 
  • The initial placebo-controlled double-blinded Phase 2 RESCUE-ALS results were strengthened further with evidence of a survival benefit and preserved function at one year and beyond.
  • In December 2022, Clene closed a debt facility with the Maryland Department of Housing and Community Development to borrow $5.0 million.
  • On March 3, 2023, Clene entered into common stock purchase agreement for up to $25.0 million with Lincoln Park Capital Fund, LLC.
  • Clene expects that its resources as of December 31, 2022, will be sufficient to fund its operations into the third quarter of 2023.

Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System

Retrieved on: 
Monday, February 27, 2023

The poster titled, “CNM-Au8 Phase 2 VISIONARY-MS Updated Trial Results,” contributes to the growing body of evidence supporting improvements in clinical neurologic function and significant paraclinical MRI and VEP findings.

Key Points: 
  • The poster titled, “CNM-Au8 Phase 2 VISIONARY-MS Updated Trial Results,” contributes to the growing body of evidence supporting improvements in clinical neurologic function and significant paraclinical MRI and VEP findings.
  • The VEP and MRI analyses presented were prespecified exploratory endpoints.
  • The updated multi-focal Visual Evoked Potential (mf-VEP) findings provide evidence of improved information transmission in the visual system (from the eye to the visual cortex) supported by statistically significant increases in amplitude.
  • These data help build a strong case in favor of pursuing CNM-Au8 in further Phase 3 studies.”

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

Retrieved on: 
Monday, February 13, 2023

The study was designed to investigate the hypothesis that supporting neuronal energy metabolism protects neurologic function in patients with MS.

Key Points: 
  • The study was designed to investigate the hypothesis that supporting neuronal energy metabolism protects neurologic function in patients with MS.
  • Exploratory endpoints, including advanced MRI imaging, within this study were designed to evaluate mechanistic and biological effects of CNM-Au8 treatment.
  • Placebo treated patients had deterioration during the 48-week treatment period, while patients treated with CNM-Au8 had preserved white matter integrity.
  • Years have been spent seeking a truly neuroprotective therapy for multiple sclerosis and other neurodegenerative diseases.

Global Hydrocephalus Shunts Market Analysis/Forecast Report 2022-2028: Business Synergy Through Strategic Alliances and Increasing Funding by Public and Private Organizations - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023

The report highlights trends prevailing in the market and factors driving the hydrocephalus shunts market growth.

Key Points: 
  • The report highlights trends prevailing in the market and factors driving the hydrocephalus shunts market growth.
  • The market growth is attributed to the increasing prevalence of hydrocephalus, and advancements in hydrocephalus valves.
  • However, the high cost of treatments involving shunts and the need for revision surgeries limit the market growth.
  • Based on product, the hydrocephalus shunts market is segmented into hydrocephalus valves, hydrocephalus catheters, neuronavigation systems, and others.

Ultra-high-res MRI Reveals Migraine Brain Changes

Retrieved on: 
Wednesday, November 23, 2022

"In people with chronic migraine and episodic migraine without aura, there are significant changes in the perivascular spaces of a brain region called the centrum semiovale," said study co-author Wilson Xu, an M.D.

Key Points: 
  • "In people with chronic migraine and episodic migraine without aura, there are significant changes in the perivascular spaces of a brain region called the centrum semiovale," said study co-author Wilson Xu, an M.D.
  • According to the American Migraine Foundation, over 37 million people in the U.S. are affected by migraine, and up to 148 million people worldwide suffer from chronic migraine.
  • "To our knowledge, this is first study using ultra-high-resolution MRI to study microvascular changes in the brain due to migraine, particularly in perivascular spaces," Xu said.
  • "Because 7T MRI is able to create images of the brain with much higher resolution and better quality than other MRI types, it can be used to demonstrate much smaller changes that happen in brain tissue after a migraine."

Cerebrum Launches Identity Pittsburgh Initiative in Partnership with Carnegie Mellon University's ETIM Program

Retrieved on: 
Thursday, September 1, 2022

PITTSBURGH, Sept. 1, 2022 /PRNewswire/ -- Cerebrum is proud to announce the launch of Identity Pittsburgh, an initiative to explore the real-world applications of Self-Sovereign Identity technology in regulated industries. The initiative, launched in partnership with Carnegie Mellon University's Engineering & Technology Innovation Management Program (CMU ETIM), will include an open to the public event series and a capstone project opportunity for CMU students.

Key Points: 
  • Cerebrum and Carnegie Mellon University's ETIM Program today announced Identity Pittsburgh, an initiative to explore the use of blockchain, cryptography, and Self-Sovereign Identity technology in regulated industries.
  • PITTSBURGH, Sept. 1, 2022 /PRNewswire/ -- Cerebrum is proud to announce the launch of Identity Pittsburgh, an initiative to explore the real-world applications of Self-Sovereign Identity technology in regulated industries.
  • The initiative, launched in partnership with Carnegie Mellon University's Engineering & Technology Innovation Management Program (CMU ETIM), will include an open to the public event series and a capstone project opportunity for CMU students.
  • With Identity Pittsburgh, Cerebrum and CMU ETIM plan to explore, analyze, and build business rationale for these use cases.